Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing - GBI Research Reports

Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing

Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing - GBI Research Reports
Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
Published Sep 01, 2011
79 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research report, Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing, which provides insights into the production methods of vaccines and into vaccine production capacity. The report discusses the egg-based and cell culture-based vaccine manufacturing processes in depth. Furthermore, details of the whole process throughput and the technologies used in vaccine manufacturing are provided in the report. It also offers a clear view of the regulatory landscapes of the US, Europe and Japan. It includes profiles of the key players and the alliances which exist in the world of vaccine manufacturing. The report explores the emerging technologies, drivers and barriers of the vaccine manufacturing process and the challenges and unmet needs present in the market.
GBI Research analysis suggests that Singapore and China are emerging as the biggest hot spots for the future of vaccine manufacturing, along with India. The vaccine manufacturing market of Singapore is growing at a rate of around 20%. Furthermore, regulatory support from the governments of these three countries is high. The in depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis also gives details of the stakeholders in the vaccine manufacturing industry and their importance within the industry. The major vaccine manufacturers are focused on acquiring new technologies and strengthening their presence in the market, by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. R&D activities also indicate the development of new technologies and novel vaccines that can revolutionize the market in the near future.

Scope

The report analyses vaccine manufacturing processes, market characterization, the regulatory landscape and the current scenario of the vaccine manufacturing industry. The report covers the following -
- Data and analysis of the global vaccine production capacity as of 2010.
- Key drivers and restraints related to the growth of the vaccine manufacturing process.
- The Regulatory landscape of the US, Europe and Japan, including the overview of the regulatory authorities in these countries.
- The Competitive landscape of the vaccine market, including profiles of the top companies. The companies studied in the report are GlaxoSmithKline, Sanofi Pasteur, Merck, Novartis, Pfizer and CSL Ltd.
- Important strategies in vaccine manufacturing, including manufacturing and outsourcing strategies.

Reasons to buy

The report will help business development and marketing executives strategize their product launches by doing the following -
- Build effective strategies by identifying the potential hotspots for vaccine manufacturing.
- Develop key strategic initiatives by studying the portfolios of the top players.
- Develop vaccine manufacturing expansion strategies by identifying drivers and restraints.
- Reinforce market entry and market expansion strategies in the US, Europe and Japan, by exploiting strong growth opportunities.
- Formulate strategies to increase your companys growth and develop new solutions for the vaccine manufacturing industry by understanding the current competitive scenario, as well as the challenges and unmet needs facing the vaccine industry.

  
Source:
Document ID
GBIHC135MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents34
  List of Tables51
  List of Figures61
Manufacturing of Vaccines - Introduction71
  GBI Research Report Guidance71
Manufacturing of Vaccines - Overview of Manufacturing82
  Upstream Bioprocessing81
  Downstream Bioprocessing81
  Methods for Producing Vaccines81
    Live Whole Virus Vaccines91
    Inactivated Whole Virus Vaccines91
    Subunit Vaccines91
    Recombinant Virus Vaccines91
    Egg-Based Vaccines91
    DNA Vaccines91
  Current Scenario of the Vaccine Manufacturing Industry91
Manufacturing of Vaccines - Role of Manufacturing in the Vaccine Industry109
  Comparison of Manufacturing of Vaccines with Manufacturing of Biologics101
  Stakeholders for Manufacturing within the Company111
    R&D Division111
    Marketing Division121
    Sales Division122
    Manufacturing Division141
      Acquisition Decisions141
      Crisis Management141
      Responsible for Timely Launch of New Product141
      Responsible for Productivity Initiatives141
      Design and Technical Support151
  Stakeholders for Manufacturing within the Industry151
    Raw Material Suppliers151
      Essential Characteristics of a Raw Material Supplier151
    Packaging Suppliers161
    Distributors172
Manufacturing of Vaccines - Vaccine Manufacturing Process1926
  Overview191
    Inactivated Influenza Vaccines191
    Live Attenuated Influenza Vaccines191
    Pandemic Influenza Vaccines191
  Raw Materials201
    Process Design201
      Sourcing201
      Volumes201
    Key Positions201
      Purchasing Managers201
    Supporting Technology211
      Bidding Processes211
  Assembly211
    Inactivated Influenza Vaccine; Egg-Based Manufacture212
    Inactivated Influenza Vaccine; Cell Culture-Based Manufacture231
    Live Attenuated Influenza Vaccines; Egg-Based Manufacture241
    Live Attenuated Influenza Vaccines; Cell-Culture Based Manufacture251
    Parvovirus B19 VLP Vaccine251
    Process Design261
      Cell Line Development261
      Mixing261
      Scale Up261
      Upstream Bioprocessing262
      Downstream Bioprocessing282
      Quality Check301
      Disposal of Waste311
    Process Throughput311
      Batch Sizes311
    Key Positions321
      Chief Scientists321
      Bioprocess Engineers321
    Supporting Technology331
      Technologies Used in Manufacturing332
  Inventory351
    Process Design351
      Inventory Management351
      Cold Storage Facilities:351
      Warehouse Management:361
      Stockpiling of Vaccines361
    Process Throughput371
      Storage Capacities371
    Key Positions371
      Logistics Managers371
  Distribution381
    Process Design381
      Warehouses and Distribution Centers381
  Challenges Faced in Vaccine Manufacturing381
    Technological Expertise381
    Initial Capital Investment391
    Regulatory Challenges391
  Unmet Needs in Vaccine Manufacturing401
    High Yield Maintenance401
    Cost411
    Time422
    Regulation441
Manufacturing of Vaccines - Vaccine Manufacturing Industry4519
  Market Characterization of Vaccine Manufacturing Industry451
    Overview451
      Costs and Timelines of Building a Manufacturing Facility451
    Vaccine Production Capacity461
    Contract Vaccine Manufacturing Market471
    Demand vs Production481
    Drivers for Growth of Vaccine Manufacturing481
      Threat of Pandemic Influenza491
      Increasing Vaccination Coverage for the Vaccines491
      Emergence of Novel Production Technologies and Vaccines491
      Population Growth501
      Economic Reasons501
    Barriers for Growth of Vaccine Manufacturing501
      Entry Barriers for the Growth of Vaccine Manufacturing:501
      Variable Demand511
      Limited Production Capacity511
  Competitive Assessment511
    Market Share511
    Profiles of Key Players511
      GlaxoSmithKline511
      Sanofi Pasteur MSD521
      Pfizer531
      Merck541
      Novartis551
      CSL Limited561
  Emerging Technologies571
    Upstream Bioprocessing571
      Emerging Production Systems571
      Efficient Filtration Mechanism571
      Recombinant Proteins and Enzymes571
    Downstream Bioprocessing571
      Disposable Reactors571
      Filtration Technologies581
  Alliances for Vaccine Manufacturing591
    Vaccine Facility Construction Alliance591
    Contract Manufacturing Alliances591
  Strategies in Vaccine Manufacturing601
    Manufacturing Strategies601
      Acquisition of Facilities611
      In-house Facilities611
    Outsourcing Strategies621
      Selection of CMOs621
      Timelines631
      CMO-Sponsor Relationship631
Manufacturing of Vaccines - Regulatory Landscape644
  The US642
  Europe661
  Japan671
Manufacturing of Vaccines - Emerging Vaccine Manufacturing Hotspots689
  Singapore681
    Regulations681
    Key Drivers and Restraints681
    Drivers691
      Regulatory Ease691
      Public Interest691
      FDI Support691
      Institutional Support691
      Government Support691
    Restraints691
      Lack of Technical Expertise691
  China701
    Regulations701
    Key Drivers and Restraints711
    Drivers721
      Government Support721
      Economy Growth Rate721
      Intellectual Property (IP) Rights Protection721
      Promising Pipeline721
      Prospective International Supplier of Raw Material721
      Growing Biological Exports721
    Restraints721
      Biogenerics versus Innovative Discoveries721
      Less Penetrated Insurance Industry721
      Establishing Quality Management731
  India741
    Regulations741
    Drivers751
      Cost Efficient751
      Supportive Government751
      Scientific Knowledge Pool751
    Restraints751
      Operational Disruptions751
      Unclear Regulations751
      Some Other Major Issues761
Manufacturing of Vaccines- Appendix773
  Market Definitions771
  Abbreviations771
  Research Methodology772
    Role of Manufacturing in the Vaccine Industry781
    The Vaccine Manufacturing Process781
    Vaccine Manufacturing Industry781
    Regulatory Landscape781
  Contact Us781
  Disclaimer791
  Sources791

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Manufacturing-of-Vaccines-Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing-2115-253>
  
APA:
GBI Research Reports. (2011). Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Manufacturing-of-Vaccines-Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing-2115-253>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.